MEGESTROL ACETATE

Post-LOE

megestrol acetate

PharmaIN

ANDAORALTABLET

Approved

Aug 1988

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

MEGESTROL ACETATE (megestrol acetate) by PharmaIN is clinical pharmacology while the precise mechanism by which megestrol produces its antineoplastic effects against endometrial carcinoma is unknown at the present time, inhibition of pituitary gonadotropin production and resultant decrease in estrogen secretion may be factors. Approved for anorexia, cachexia, an unexplained and 1 more indications. First approved in 1988.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY While the precise mechanism by which megestrol produces its antineoplastic effects against endometrial carcinoma is unknown at the present time, inhibition of pituitary gonadotropin production and resultant decrease in estrogen secretion may be factors. There is evidence to…

Worked on MEGESTROL ACETATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (10)

NCT06961188Phase 3Not Yet Recruiting

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Started Jun 2025

174 enrolled

Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene NegativityUntreated With Systemic Therapy

NCT04939090Phase 3Active Not Recruiting

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Started Jan 2022

227 enrolled

Advanced Malignant Solid NeoplasmAnorexiaHematopoietic and Lymphoid Cell Neoplasm

NCT01650168N/ACompleted

Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)

Started Jul 2012

101,498 enrolled

Contraception

NCT00910091Phase 2Completed

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Started Aug 2009

73 enrolled

Endometrial Cancer

NCT01237327Phase 3Completed

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Started Nov 2001

84 enrolled

Metastatic Breast Cancer

MEGESTROL ACETATE

Mechanism of Action

Indications (4)

Clinical Trials (10)